Abstract
Therapeutic approaches seeking to limit the exposure to antiretroviral drugs while retaining the benefits of continuous therapy have become an active area of investigation in HIV therapy research. Although early attempts to use interruptions of therapy as auto-vaccination strategies have shown little success, much has been discovered in regards to immunological correlates of viral control in acute and chronic infection, viral evolution, and the safety of single or multiple therapy interruptions in different patient sub-groups (acutely infected, chronically infected, and multi-drug resistant). Here we review safety data and candidate factors that may contribute to the striking differences observed between patients that undergo similar treatment interruption strategies but achieve different outcomes in controlling HIV replication. Differences between acute and chronic infection in the viral component (e.g. diversity of the viral pool) and the host immune system (e.g. low avidity CTL memory response), which may not be reversed by ART, may determine the potential for suppressive immune response upon therapy interruption. Consistent with goals of limiting toxicity and cost of antiretroviral drug regimens, safety outcomes to date indicate that intermittent therapy strategies may safely continue to be investigated in early and chronically infected patients. Based on ongoing research, we identify the topics to be targeted in future studies.
Keywords: sti, hiv-1, haart, antiretroviral therapy, intermittent therapy, cellular immunity, structured therapy interruption
Current HIV Research
Title: Lessons Learned from HIV Treatment Interruption: Safety, Correlates of Immune Control, and Drug Sparing
Volume: 1 Issue: 3
Author(s): Livio Azzoni, Emmanouil Papasavvas and Luis J. Montaner
Affiliation:
Keywords: sti, hiv-1, haart, antiretroviral therapy, intermittent therapy, cellular immunity, structured therapy interruption
Abstract: Therapeutic approaches seeking to limit the exposure to antiretroviral drugs while retaining the benefits of continuous therapy have become an active area of investigation in HIV therapy research. Although early attempts to use interruptions of therapy as auto-vaccination strategies have shown little success, much has been discovered in regards to immunological correlates of viral control in acute and chronic infection, viral evolution, and the safety of single or multiple therapy interruptions in different patient sub-groups (acutely infected, chronically infected, and multi-drug resistant). Here we review safety data and candidate factors that may contribute to the striking differences observed between patients that undergo similar treatment interruption strategies but achieve different outcomes in controlling HIV replication. Differences between acute and chronic infection in the viral component (e.g. diversity of the viral pool) and the host immune system (e.g. low avidity CTL memory response), which may not be reversed by ART, may determine the potential for suppressive immune response upon therapy interruption. Consistent with goals of limiting toxicity and cost of antiretroviral drug regimens, safety outcomes to date indicate that intermittent therapy strategies may safely continue to be investigated in early and chronically infected patients. Based on ongoing research, we identify the topics to be targeted in future studies.
Export Options
About this article
Cite this article as:
Azzoni Livio, Papasavvas Emmanouil and Montaner J. Luis, Lessons Learned from HIV Treatment Interruption: Safety, Correlates of Immune Control, and Drug Sparing, Current HIV Research 2003; 1 (3) . https://dx.doi.org/10.2174/1570162033485212
DOI https://dx.doi.org/10.2174/1570162033485212 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antiviral Profile of HIV Inhibitors in Macrophages: Implications for Therapy
Current Topics in Medicinal Chemistry Signaling Intermediates (PI3K/PTEN/AKT/mTOR and RAF/MEK/ERK Pathways) as Therapeutic Targets for Anti-Cancer and Anti-Angiogenesis Treatments
Current Signal Transduction Therapy Nitric Oxide: News from Stem Cells to Platelets
Current Medicinal Chemistry Natural Products: A Rich Source of Antiviral Drug Lead Candidates for the Management of COVID-19
Current Pharmaceutical Design Polymer Structures for Sensors and Actuators 1. Analyte Biosensor
Recent Patents on Materials Science Anti-Atherogenic Role of Peroxisome Proliferator-Activated Receptor Ligands
Current Cardiology Reviews Coreceptor Switch in Infection of Nonhuman Primates
Current HIV Research Long Term Outcome of Infants with NEC
Current Pediatric Reviews Mitochondrial Dysfunction and Oxidative Stress in Insulin Resistance
Current Pharmaceutical Design Clinical PET Imaging of Insulinoma and Beta-Cell Hyperplasia
Current Pharmaceutical Design Beneficial Neurobiological Effects of Melatonin Under Conditions of Increased Oxidative Stress
Current Medicinal Chemistry - Central Nervous System Agents Flavonoids in Human Health: From Structure to Biological Activity
Current Nutrition & Food Science Ubiquitin-Protein Ligases - Novel Therapeutic Targets?
Current Protein & Peptide Science The Nef-Infectivity Enigma: Mechanisms of Enhanced Lentiviral Infection
Current HIV Research New Concepts for Glaucoma Implants - Controlled Aqueous Humor Drainage, Encapsulation Prevention and Local Drug Delivery
Current Pharmaceutical Biotechnology Targeted Nucleic Acid Delivery to Mitochondria
Current Gene Therapy Role of Inflammation in the Development of Colorectal Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Recently Patented Viral Nucleotide Sequences and Generation of Virus-Derived Vaccines
Recent Patents on Anti-Infective Drug Discovery Targeting Natural Products for the Treatment of COVID-19 – An Updated Review
Current Pharmaceutical Design Molecular Insights into Mechanisms of the Cell Death Program:Role in the Progression of Neurodegenerative Disorders
Current Alzheimer Research